Lestaurtinib - Small Molecule (ID:10230-101)
| HMS LINCS ID: |
10230-101
|
| Name: | Lestaurtinib |
| Alternative Names: | CEP-701 |
| LINCS ID: | LSM-1231 |
| PubChem CID: | 126565 |
| ChEBI ID: | |
| ChEMBL ID: | |
| Molecular Mass: | 439.15 |
| InChi: | InChI=1S/C26H21N3O4/c1-25-26(32,12-30)10-18(33-25)28-16-8-4-2-6-13(16)20-21-15(11-27-24(21)31)19-14-7-3-5-9-17(14)29(25)23(19)22(20)28/h2-9,18,30,32H,10-12H2,1H3,(H,27,31)/t18-,25+,26+/m1/s1 |
| InChi Key: | UIARLYUEJFELEN-LROUJFHJSA-N |
| SMILES: | C[C@@]12[C@](C[C@@H](O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)(CO)O |
| Relevant Citations: | |
| Comments: | |
| Date Publicly Available: | |
| Most Recent Update: | 2016-04-04 |
Target Affinity:
(see Study 20000)| Target Affinity Spectrum Value | HUGO Gene Name |
|---|---|
AAK1, ACVR1, ACVR1B, AIM1, ALK, ANKK1, AURKA, AURKB, AURKC, AXL, BMP2K, BMPR1B, BRSK1, BRSK2, BTK, BUB1B-PAK6, C8orf44-SGK3, CAMK1D, CAMK2A, CAMK2B, CAMK2D, CAMK2G, CAMKK1, CAMKK2, CDK16, CDK2, CDK4, CDK7, CDKL2, CDKL5, CHEK1, CHUK, CIT, CLK1, CLK2, CLK4, DAPK1, DAPK2, DAPK3, DSTYK, DYRK1A, DYRK1B, DYRK2, EIF2AK4, EPHB6, ERN1, FER, FGR, Flt3, FLT3, FLT4, FYN, GAK, GRK1, GRK4, GRK7, ICK, IKBKB, IKBKE, IRAK1, IRAK3, IRAK4, JAK1, JAK2, JAK3, KIT, LATS1, LATS2, LRRK2, MAP2K1, MAP2K2, MAP2K3, MAP2K4, MAP2K5, MAP2K6, MAP2K7, MAP3K10, MAP3K11, MAP3K15, MAP3K19, MAP3K2, MAP3K3, MAP3K5, MAP3K7, MAP3K9, MAP4K1, MAP4K2, MAP4K4, MAP4K5, MAPK10, MAPK15, MAPK8, MARK1, MARK2, MARK3, MAST1, MELK, MERTK, MINK1, MKNK1, MKNK2, MST1, MYLK, MYLK2, MYLK3, MYLK4, NTRK1, NTRK2, NTRK3, NUAK1, NUAK2, PAK1, PAK2, PAK3, PAK4, PAK5, PAK6, PDGFRB, PDK1, PDPK1, PF3D7_0217500, PHKG1, PHKG2, PIM3, PIP4K2B, PIP5K1A, PKD1, PKD2, PKN1, PKN2, pknB, PLK4, PRKAA1, PRKAA2, PRKD1, PRKD2, PRKD3, PRKG2, PRKX, PTK2B, RET, RIOK1, RIOK3, RIPK4, ROCK1, ROCK2, ROS1, RPS6KB1, SGK3, SIK1, SIK1B, SIK2, SLK, SRPK1, SRPK2, SRPK3, STK10, STK11, STK16, STK17A, STK17B, STK25, STK3, STK33, STK4, SYK, TAOK1, TAOK3, TBK1, TLK2, TNIK, TNK1, TNK2, TNKS2, TSSK1B, TTK, ULK2, ULK3, ZAP70 | |
2 (equivalent to 100 nM ≤ Kd < 1µM) | ABL1, BLK, BMPR1A, BMX, CAMK1, CAMK1G, CASK, CDK14, CDK17, CDK3, CDK5, CDK9, CDKL1, CDKL3, CDKN3, CHEK2, CSF1R, CSK, CSNK2A2, DDR1, DDR2, DLK1, DMPK, EGFR, EIF2AK2, EPHA1, EPHA2, EPHA3, EPHA7, FES, FGFR1, FGFR2, FGFR3, FLG, FLT1, FRK, HCK, HIPK1, HIPK2, HIPK3, HIPK4, HUNK, ITK, KDR, LCK, LTK, LYN, MAP3K12, MAP3K13, MAP3K6, MAP4K3, MAPK12, MAPK9, MAPKAPK2, MAPKAPK5, MARK4, MATK, MET, MYO3A, MYO3B, NLK, PDGFRA, PI4KB, PIK3C2G, PIK3CG, PIM1, PIM2, PLK1, PLK2, PRKACA, PRKACB, PRKCA, PRKCD, PRKCE, PRKCH, PRKCQ, PRKG1, PRPF4, PRPF4B, RIPK2, RPS6KA1, RPS6KA2, RPS6KA3, RPS6KA4, RPS6KA5, SBK1, SBK3, SIK3, SRC, SRMS, STK24, STK26, STK35, STK38, STK38L, TAOK2, TEK, TESK1, TGFBR1, TGFBR2, TIE1, TKT, TLK1, TXK, TYK2, TYRO3, YES1 |
3 (equivalent to 1µM ≤ Kd < 10 µM) | ABL2, ACVR2A, ACVR2B, ACVRL1, AKT1, AKT2, AKT3, BMPR2, CAMK4, CDC42BPA, CDC42BPB, CDC42BPG, CDK13, CDK15, CDK8, CSNK1A1L, CSNK2A1, DCLK2, DCLK3, EPHA4, EPHA5, EPHA6, EPHB1, EPHB2, EPHB4, ERBB3, ERBB4, FGFR4, FPGT-TNNI3K, GSK3A, GSK3B, IGF1R, INSR, INSRR, LIMK1, MAK, MAP3K1, MAP3K20, MAP3K4, MAPK13, MAPK3, MAPK7, MST1R, MUSK, NEK1, NEK2, NEK5, NEK6, NEK7, NEK8, NEK9, NIM1K, OSR1, OXSR1, PF3D7_1356900, PIK3C2B, PIK3CA, PIK3CB, PIK3CD, PLK3, PRKCI, PTK2, PTK6, RIOK2, RPS6KA6, STK32A, STK32B, STK32C, STK36, STK39, TEC, TNNI3K, ULK1, WEE1, WEE2 |
10 (confirmed non-binding) |
Datasets:
| HMS Dataset ID | Dataset Title | HMS Dataset Type |
|---|---|---|
| 20000 | Target Affinity Spectrum (TAS) vectors for compounds in the HMS LINCS small molecule library. | Analysis |
| 20120 | Metrics other than potency reveal systematic variation in responses to cancer drugs | Analysis |
| 20233 | Synovial Fibroblast 1: Secretion response of primary human synovial fibroblast samples from one healthy and one rheumatoid arthritis donor to a panel of 10 stimuli and 10 small molecule inhibitors | Bead-based immunoassay |
| 20268 | Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. | Analysis |
| 20269 | Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 2 of 4: Calculated dose-response metrics. | Analysis |
| 20270 | Growth rate-corrected (GR) dose-response metric signatures across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 3 of 4: Median, upper quartile, and lower quartile GR metrics per perturbagen. | Analysis |
Batch Information:
| HMS LINCS Batch ID | Provider | Provider Batch ID |
|---|---|---|
| 10230-101-1 | Tocris | reference date: Oct 2010 |
| 10230-101-2 | LC Laboratories | |
| 10230-101-3 | LC Laboratories |
(Kd <100 nM)